Specifically, TGF-β released by cancer cells binds to chondroitin sulfate in the ECM, which enhances TGF-β signaling, facilitates the epithelial-mesenchymal transition (EMT), and induces the ABCB1 drug transporter (Hoshiba and Tanaka, 2016). The gene discussed is TGFB1; the disease is cancer.